← Back to research

RESEARCH NOTE · 01

R3TTA
(RATATOUILLE)

An investigational triple hormone-receptor agonist designed to engage GIP, GLP-1, and glucagon signaling pathways.

STATUS InvestigationalPATHWAYS GIP · GLP-1 · Glucagon
R3TTA
GIPGLP-1GLUCAGON
01
R3TTA (RATATOUILLE) is the journal's shorthand for an investigational peps designed to activate three receptor systems: GIP, GLP-1, and glucagon. The molecule has become a major subject of metabolic research because researchers can study coordinated signaling across all three pathways.

RESEARCH SNAPSHOT

Research-associated effects

Areas of effect or outcome that researchers have investigated or reported in the literature. These are research associations, not guarantees of a particular result.

RESEARCH AREABody-weight reduction in clinical research
RESEARCH AREAAppetite and food-intake regulation
RESEARCH AREAGlucose and broader metabolic measures
RESEARCH AREACombined GIP / GLP-1 / glucagon pathway activity

Evidence varies by compound, model, formulation, route, endpoint, and study design. Component-level findings do not automatically establish the same effect for a blend.

02

THE THREE-PATHWAY MODEL

Three signals.
One molecule.

PATHWAY 01GIPGIP receptor
PATHWAY 02GLP-1GLP-1 receptor
PATHWAY 03GLUCAGONglucagon receptor

Researchers are interested in whether coordinated activation of these pathways can produce a different metabolic profile from activating one or two pathways alone. The informal phrase “GLP-3” is sometimes used online, but it is not a formal scientific classification.

03

THE RESEARCH QUESTION

Why researchers
are studying it

Clinical research has examined effects on body weight and metabolic measures in adults with overweight or obesity. A 2023 phase 2 randomized trial reported dose-dependent reductions in body weight over 48 weeks. Those results supported continued clinical development, but an investigational result is not the same thing as regulatory approval.

48
WEEKSof treatment in the published phase 2 trial

The key research distinction is between a measured clinical-trial result and a claim about what the molecule should be used for. The former is evidence; the latter requires regulatory and clinical context.

04

CURRENT STATUS

Where the research
stands.

R3TTA remains investigational as of 2026. Continued phase 3 development and regulatory review are the next steps in determining its eventual status.

INVESTIGATIONAL

Research findings do not by themselves establish approval, safety for self-administration, or suitability for human use outside an approved clinical setting.

RESEARCH SOURCING

Looking for research materials?

The supplier reference is provided for research-use sourcing only and is not an endorsement of safety, efficacy, regulatory approval, or human use.

Research Supplier ↗

PRODUCT PREVIEW

View this catalog item

Open Ridgestone Labs to preview available catalog listings. Checkout, if available, takes place on the supplier's website.

Preview & checkout at RidgestoneLabs.info ↗

Editorial note: Educational research commentary only. This page does not provide dosing instructions, prescribing information, or a recommendation for human use.

Sources: published clinical-trial literature; FDA regulatory materials.